Kristopher V Waynant

Prof. Dr. Kristopher V Waynant


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2017 in Journal of Chemical Education
Verified
Journal Article
Closed access
DFDaniel E. Felton
Daniel E. Felton
MEMartina Ederer
Martina Ederer
TSTimothy Steffens
Timothy Steffens
PHPatricia L. Hartzell
Patricia L. Hartzell
KWKristopher V Waynant
Kristopher V Waynant

22 February 2023 in Organometallics
Verified
Journal Article
Closed access
RPRabina Pradhan
Rabina Pradhan
KGKaylaa L. Gutman
Kaylaa L. Gutman
AUAbu Mas Ud
Abu Mas Ud
EHElliott B. Hulley
Elliott B. Hulley
KWKristopher V Waynant
Kristopher V Waynant

26 November 2017 in European Journal of Inorganic Chemistry
Verified
Journal Article
Closed access
PDF file
NJNicolas A. Johnson
Nicolas A. Johnson
SWSamuel R. Wolfe
Samuel R. Wolfe
HKHumayun Kabir
Humayun Kabir
GAGabriel A. Andrade
Gabriel A. Andrade
GYGlenn P. A. Yap
Glenn P. A. Yap
KWKristopher V Waynant
Kristopher V Waynant

19 June 2023 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
RPRabina Pradhan
Rabina Pradhan
LTLaxmi Tiwari
Laxmi Tiwari
VGVincent M. Groner
Vincent M. Groner
CLCaleb Leach
Caleb Leach
KLKyle Lusk
Kyle Lusk
KWKristopher V Waynant
Kristopher V Waynant

12 July 2022 in Journal of Chemical Education
Verified
Journal Article
Closed access
CSCarson Silsby
Carson Silsby
RMRoslyn McCormack
Roslyn McCormack
MRMark F. Roll
Mark F. Roll
JMJames Moberly
James Moberly
KWKristopher V Waynant
Kristopher V Waynant

20 August 2024 in ACS Omega
Verified
Journal Article
Open access
LTLaxmi Tiwari
Laxmi Tiwari
CLCaleb Leach
Caleb Leach
AWAshley Williams
Ashley Williams
BLBrandon Lighter
Brandon Lighter
ZHZachariah Heiden
Zachariah Heiden
KWKristopher V Waynant
Kristopher V Waynant
Finding new sources of biologically active compounds for anticancer or antimicrobial therapies remains an active area of research. Azothioformamides (ATFs) with a 1,3 N=N-C=S heterodiene backbone are a new class of biologically active compounds that chelate metals (e.g., Cu) forming stable ATF metal coordination complexes. In this study, ATF ligands were prepared with pyrrolidine, piperidine, N-methylpiperazine, and morpholine substituents on the formamide as to add more heterocyclic drug-like character for biological studies. Formamide derivatives were then complexed with various Cu(I) salts to form coordination complexes. Cu(I) salts were selected as to create potential bioactive compounds with less toxicity. Binding association constants of each Cu(I) salt to ATF ligands were extrapolated from UV-vis titration studies and were corroborated with DFT calculations using a hybrid functional B3LYP method. It was observed that the smaller pyrrolidine functionalized ATFs bound to the Cu(I) salts had stronger binding than any of the larger six-membered-ring heterocycles with association values in the 104 - 105 M-1 range. The ATF-Cu(I) salt coordination complexes were then evaluated for antimicrobial activity against two bacteria (Staphylococcus aureus, Escherichia coli), one yeast (Candida albicans), four human cancer lines (A-549, K-562, HT-1080, MDA-MB-231), and two normal human lines (MRC-5, HFF). The ATF ligands themselves were inactive against all microbes and most human lines except K-562 cells, which were sensitive to three of the four ligands (IC50's = 7.0-25.5 μM). Most ATF-Cu(I) complexes showed low to medium micromolar activity against Candida albicans (IC50's 2.6-24.8 μM) and Staphylococcus aureus (IC50's = 3.4-37.7 μM), with increasing activity corresponding to complexes with higher binding association constants. The antiproliferative properties of ATF-Cu(I) metal salt complexes against mammalian cells were mixed, with low to medium micromolar activity across all cell lines. Notably, several ATF-Cu(I) salt coordination complexes showed submicromolar activity against the HT-1080 fibrosarcoma line (0.52-0.69 μM). The results demonstrate promising activity of ATF-Cu(I) complexes, particularly with pyrrolidine as the formamide component. These studies suggest that the stronger binding association values correlate to higher levels of biological activity.